Delving into the Latest Updates on SRM Institute of Science and Technology with Synapse

Overview

Tags

Urogenital Diseases

Neoplasms

Endocrinology and Metabolic Disease

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	4
Endocrinology and Metabolic Disease	4
Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	5

Top 5 Target	Count

PARP1 x PARP2	4
ACHE(Acetylcholinesterase)	1

A Prospective randomized and double blinded study comparing duration of post operative analgesia between ultrasound guided Interscalene block with Ropivacaine 0.5 percent and Interscalene block with Ropivacaine 0.5 percent and Dexmedetomidine as adjuvant for shoulder arthroscopic surgeries done under General anesthesia - Nil

Start Date20 Apr 2025

Sponsor / Collaborator

SRM Institute of Science and Technology

CTRI/2025/04/084244

/ Not yet recruitingNot Applicable

Multifaceted investigation of NFAT and FOXP3 genetic variants in migraine susceptibility A combined genome wide association study and immune profiling pathway approach in an Indian population - NIL

Start Date15 Apr 2025

Sponsor / Collaborator

SRM Institute of Science and Technology

100 Clinical Results associated with SRM Institute of Science and Technology

Login to view more data

0 Patents (Medical) associated with SRM Institute of Science and Technology

Login to view more data

788

Literatures (Medical) associated with SRM Institute of Science and Technology

01 Jun 2025·Journal of Nonlinear Optical Physics & Materials

A noncentrosymmetric polymorph of second harmonic generation 2,4 dinitrophenyl hydrazine for nonlinear optical applications: An experimental and theoretical investigation

Author: Saravanan, M. ; Praveen, B.

Potent ocular materials with noncentrosymmetric frameworks seek the attention of researchers throughout the globe. A polymorph of 2,4-dinitrophenylhydrazine single crystals with such framework was grown by slow cooling mechanism with 1,4-dioxane as the solvent. The noncentrosymmetric characteristics of the grown material were confirmed by using X-ray diffraction analysis. The presence of functional groups of the title meld was identified with the aid of Fourier transform infrared spectroscopy analysis. The ability of the material to withstand temperature with weight loss and decomposition peak was determined by using TG/DTA analysis. The transmission window and optical bandgap of the materials were determined by using UV–Vis analysis. The nonlinear optical behavior of the grown crystals was determined with the aid of SHG and Z-scan analysis. The computational analysis was performed using Gaussian 09 software package to investigate various parameters of title meld. Hirshfeld surface analysis was performed using Crystal explorer 17 to quantify the intermolecular interactions of the grown material.

15 Apr 2025·IEEE Sensors Journal

Classification of Gait Phases Using a Shank-Mounted Single IMU Sensor

Author: Bhatia, Manvir ; Gandhi, Tapan Kumar ; Gupta, Rohit ; Bhongade, Amit ; Prathosh, A. P.

04 Mar 2025·2025 International Conference on Visual Analytics and Data Visualization (ICVADV)

Weather Data Analysis and Visualization Using PySpark and PowerBI

Author: Khatri, Garv ; Dash, Bivanshu ; Sinha, Abhijat ; P, Gouthaman

100 Deals associated with SRM Institute of Science and Technology

Login to view more data

100 Translational Medicine associated with SRM Institute of Science and Technology

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 13 Jul 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

4

Preclinical

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

(+)-Zampanolide ( PARP1 x PARP2 )	Ovarian Serous Tumor More	Preclinical
Alisiaquinone C ( PARP1 x PARP2 )	Ovarian Serous Tumor More	Preclinical
Alisiaquinone A ( PARP1 x PARP2 )	Ovarian Serous Tumor More	Preclinical
Ascomindone D ( PARP1 x PARP2 )	Ovarian Serous Tumor More	Preclinical
IN202441059033 ( ACHE )	Alzheimer Disease More	Discovery